{
  "docId": "019de074-7886-752e-a283-7bf57c077b30",
  "docSlug": "0ac137ebdbf597da5ec73bb0ea218c10",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 31,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a split-layout with a left-hand sidebar for product specs and a right-hand main area for clinical evidence and trial design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7886-752e-a283-7bf57c077b30/22",
  "deckHref": "/decks/019de074-7886-752e-a283-7bf57c077b30",
  "deckJsonHref": "/decks/019de074-7886-752e-a283-7bf57c077b30.json",
  "deckAnchorHref": "/decks/019de074-7886-752e-a283-7bf57c077b30#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.6,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Third Party Study: Non Inferiority Test (Ham-A total score)",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1534fc57-3613-440d-acba-3654d950e5b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.6,
        "x": 0.37,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Completed Phase 1 Trial: Part 1 Single Ascending Dose and Part 2 Multiple Ascending Dose",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd56ce13-54af-4f06-8d41-1c4a532cac88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.3,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "list",
      "text": "Ownership, Product, Pharmacology, Product Features, Indications, Current Status, Intellectual Property, Highlight",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41305ddc-1ece-41f3-b1ba-4360866bd559",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.37,
        "y": 0.32
      },
      "kind": "paragraph",
      "text": "Etifoxine works as rapidly as lorazepam, with etifoxine continuing its effects beyond treatment, while lorazepam shows rebound. Etifoxine has a strong safety record.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f3042dc-adf3-46b5-b387-e8f45d73391a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: HAM-A = Hamilton Anxiety Rating Scale, SD = standard deviation, qEEG = Quantitative electroencephalography, PK = Pharmacokinetics. PD = Pharmacodynamics, PoC = Proof of Concept.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27d94dcb-b3d3-418c-baf9-f010dc55503e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.07
      },
      "kind": "title",
      "text": "GRX-917 has the potential for benzodiazepine-like rapid-onset efficacy with improved safety and tolerability",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8a7d085-b078-4a98-9829-10e6080d04fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY: GRX-917",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cd20d7c-c8d3-4a5e-b2d8-71cc54363863",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "b10b1290-1796-4eea-a79b-9ab75f32e77b",
      "evidence": "The headline summarizes the key takeaway of the slide.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "7fd3e95d-372d-48f7-909d-f8c5c51d3874",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document highlights various traction points, including clinical study results and data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}